TWST / Twist Bioscience Clocks ~50% Jump In Q1 Sales, Lifts FY22 Revenue Guidance

Today, we take a look synthetic biology company Twist Bioscience Corporation for the first time since spring. The company recently signed collaboratio more_horizontal

Twist continues to expand its SynBio and NGS businesses, but its Biopharma business has had execution issues. Twist is focused on reducing costs, but more_horizontal

Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corpo more_horizontal

Twist makes synthetic biology and next-generation sequencing tools. The company reported improved revenue and reduced losses in the quarter. more_horizontal

Twist Bioscience (TWST) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to los more_horizontal

The stock of Twist Bioscience Corporation has declined more than 60% since our first peek at it in the fall of last year. However, the stock saw its f more_horizontal

Twist Bioscience (TWST) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to los more_horizontal

Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR ge more_horizontal